Inclusion Body Myositis Therapeutics Market Size in the 7MM is anticipated to increase at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Inclusion Body Myositis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology as well as the Inclusion Body Myositis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Inclusion Body Myositis Market with DelveInsight’s In-Depth Report @ Inclusion Body Myositis Market Size

Key Takeaways from the Inclusion Body Myositis Market Report

• The prevalence of IBM is about 5 to 9 cases per million adults, and it varies with factors like geographic area, ethnicity, and age.
• In the US, the estimated number of IBM cases is approximately 20,000 to 25,000.
• IBM usually develops after the age of 50 and is more likely to affect men than women.
• The mean age at symptom onset for patients grouped by presenting symptom was 64.8 years for quadriceps weakness, 62.2 years for finger flexor weakness, and 67.7 years for swallowing difficulties, respectively.
• IBM remains one of the most underrepresented subtypes within idiopathic inflammatory myopathies (IIMs), with rheumatologists citing it as particularly underserved amid increasing calls for faster, safer, and steroid-sparing treatments.
• The leading Inclusion Body Myositis Companies such as Abcuro, and others.
• Promising Inclusion Body Myositis Therapies such as Ulviprubart (ABC008), and others.

Stay ahead in the Inclusion Body Myositis market research with DelveInsight’s Strategic Report @ Inclusion Body Myositis Market Outlook

Inclusion Body Myositis Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of IBM
• Age-specific Cases of IBM
• Gender-specific Cases of IBM

Download the report to understand which factors are driving Inclusion Body Myositis market insight @ Inclusion Body Myositis Prevalence

Marketed Inclusion Body Myositis Therapies 

There are currently no FDA-approved therapies for IBM. Management relies on off-label drugs such as glucocorticoids, methotrexate, cyclophosphamide, azathioprine, intravenous immunoglobulin (IVIG), and alemtuzumab used in clinical practice. However, these off-label drugs offer limited or inconsistent benefit, leading to an unmet need for effective disease-modifying therapies. Management is primarily supportive, focusing on maintaining mobility and function through physical and occupational therapy, preventing falls, and addressing complications such as dysphagia with dietary modifications or swallowing therapy.

Emerging Inclusion Body Myositis Therapies

• Ulviprubart (ABC008): Abcuro Ulviprubart is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing naïve, regulatory, and central memory T cells. Ulviprubart has been designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM). It is being evaluated in Phase II/III of development for the treatment of IBM. In March 2025, Abcuro announced that they had presented safety, pharmacokinetic, and pharmacodynamics data from the Phase I clinical trial evaluating ulviprubart for the treatment of IBM at the American Academy of Neurology (AAN) Annual Meeting. In June 2024, Abcuro announced the completion of enrollment of the registrational Phase II/III MUSCLE clinical trial evaluating ulviprubart for the treatment of IBM.

To know more about Inclusion Body Myositis treatment guidelines, visit @ Inclusion Body Myositis Treatment Market Landscape

Inclusion Body Myositis Therapies and Companies

• Ulviprubart (ABC008): Abcuro

Inclusion Body Myositis Market Dynamics The Inclusion Body Myositis market dynamics have undergone significant changes over the years. IBM remains one of the most underrepresented subtypes within idiopathic inflammatory myopathies, with rheumatologists citing it as particularly underserved. The lack of FDA-approved therapies creates a significant unmet need and opportunity for pharmaceutical companies to develop the first effective disease-modifying treatments. Several late-stage IBM drug programs have been discontinued, including bimagrumab (Novartis) for lack of functional benefit, arimoclomol (Orphazyme) for failing key endpoints, and sirolimus for limited efficacy and substantial side effects. These setbacks have substantially reduced IBM’s pipeline, leaving only a limited number of candidates in development. Current innovation in IBM is focused on targeted immunotherapies like ulviprubart, which aim to slow disease progression, enhance muscle function, and address the limited effectiveness of conventional off-label treatments. The aging population also serves as a driver, as IBM typically affects individuals over 50, creating a growing patient pool for effective therapies.

Learn more about the emerging therapies for Inclusion Body Myositis @ Drugs for Inclusion Body Myositis Treatment

Scope of the Inclusion Body Myositis Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Forecast Period – 2025-2034
• Inclusion Body Myositis Companies- Abcuro, and others
• Inclusion Body Myositis Therapies- Ulviprubart (ABC008), and others
• Inclusion Body Myositis Unmet Needs, KOL’s views, Analyst’s views, Inclusion Body Myositis Market Access and Reimbursement

Table of Content

1. Key Insights
2. Executive Summary of Inclusion Body Myositis
3. Competitive Intelligence Analysis for Inclusion Body Myositis
4. Inclusion Body Myositis: Market Overview at a Glance
5. Inclusion Body Myositis: Disease Background and Overview
6. Patient Journey
7. Inclusion Body Myositis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Inclusion Body Myositis Unmet Needs
10. Key Endpoints of Inclusion Body Myositis Treatment
11. Inclusion Body Myositis Marketed Products
12. Inclusion Body Myositis Emerging Therapies
13. Inclusion Body Myositis: Seven Major Market Analysis
14. Attribute Analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Inclusion Body Myositis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com